Study to Evaluate the Safety and Efficacy of SDP-4 in Subjects With Dry Eye Disease (DED)
Status:
Completed
Trial end date:
2019-10-11
Target enrollment:
Participant gender:
Summary
SDP-4-CS201, is a Phase 2, multi-center, double-masked, randomized, vehicle-controlled,
dose-response, parallel-group study designed to evaluate the ocular and systemic safety and
efficacy of SDP-4 ophthalmic solution in subjects with moderate to severe dry eye disease
over a 12-week treatment period. Three concentrations (0.1%, 1.0% and 3.0%) of SDP-4
ophthalmic solution will be given to parallel groups via topical ocular instillation BID.